Literature DB >> 9207439

Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia.

A L Petzer1, C J Eaves, M J Barnett, A C Eaves.   

Abstract

We have previously reported that primitive normal hematopoietic cells detectable as long-term culture-initiating cells (Ph-LTC-IC) are present at high levels in the blood of some patients with chronic myeloid leukemia (CML). We now show that this population can be expanded several-fold when highly purified CD34+CD38- cells isolated from the blood of such patients are cultured for 10 days in a serum-free medium containing 100 ng/mL of Flt3-ligand and Steel factor and 20 ng/mL of interleukin-3 (IL-3) and IL-6, and granulocyte colony-stimulating factor. In similar cultures initiated with CD34+CD38- cells from CML blood samples in which all of the LTC-IC were leukemic (Ph+), Ph+ LTC-IC activity was rapidly lost both in the presence and absence of admixed CD34+CD38- cells isolated from normal marrow. Conversely, the ability of normal LTC-IC to expand their numbers was shown to be independent of the presence of Ph+LTC-IC and later types of Ph+colony-forming cell (CFC) progenitors. In contrast to the LTC-IC, CFC were consistently amplified in cultures initiated with CML-derived CD34+CD38- cells and the additional CFC present after 10 days were, like the starting population of CFC, almost exclusively Ph+ regardless of the genotype(s) of the LTC-IC in the original CML samples. Amplification of the Ph+CFC population in these cultures showed the same factor dependence as previously demonstrated for the in vitro expansion of CFC from normal marrow CD34+CD38- cells. Ph+LTC-IC disappeared regardless of the cytokines present. Taken together these findings support a model of CML in which the leukemic stem cells are characterized by a decreased probability of self-renewal and an increased probability of differentiation. In addition, they suggest new opportunities for improving the treatment of CML using strategies that require autologous stem cell rescue.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9207439

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.

Authors:  Shengming Zhao; Karen Zoller; Masayoshi Masuko; Ponlapat Rojnuckarin; Xuexian O Yang; Evan Parganas; Kenneth Kaushansky; James N Ihle; Thalia Papayannopoulou; Dennis M Willerford; Tim Clackson; C Anthony Blau
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

2.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Authors:  Mirle Schemionek; Christian Elling; Ulrich Steidl; Nicole Bäumer; Ashley Hamilton; Tilmann Spieker; Joachim R Göthert; Martin Stehling; Amy Wagers; Claudia S Huettner; Daniel G Tenen; Lara Tickenbrock; Wolfgang E Berdel; Hubert Serve; Tessa L Holyoake; Carsten Müller-Tidow; Steffen Koschmieder
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

3.  Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.

Authors:  B Douglas Smith; Richard J Jones; Eunpi Cho; Jeanne Kowalski; Judith E Karp; Steven D Gore; Milada Vala; Brooke Meade; Sharyn D Baker; Ming Zhao; Steven Piantadosi; Zhe Zhang; Gideon Blumenthal; Erica D Warlick; Robert A Brodsky; Anthony Murgo; Michelle A Rudek; William H Matsui
Journal:  Leuk Res       Date:  2010-07-03       Impact factor: 3.156

4.  In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.

Authors:  Amos Gaikwad; Roberto Nussenzveig; Enli Liu; Stephen Gottshalk; KoTung Chang; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

5.  Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients.

Authors:  Hanno Glimm; Manfred Schmidt; Marlene Fischer; Kerstin Schwarzwaelder; Manuela Wissler; Silke Klingenberg; Claudia Prinz; Cornelius F Waller; Winand Lange; Connie J Eaves; Christof von Kalle
Journal:  Blood       Date:  2005-04-21       Impact factor: 22.113

6.  Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Authors:  Yashodhara Dasgupta; Mateusz Koptyra; Grazyna Hoser; Kanchan Kantekure; Darshan Roy; Barbara Gornicka; Margaret Nieborowska-Skorska; Elisabeth Bolton-Gillespie; Sabine Cerny-Reiterer; Markus Müschen; Peter Valent; Mariusz A Wasik; Christine Richardson; Oliver Hantschel; Heiko van der Kuip; Tomasz Stoklosa; Tomasz Skorski
Journal:  Blood       Date:  2016-02-10       Impact factor: 22.113

7.  Evolutionary dynamics of chronic myeloid leukemia.

Authors:  David Dingli; Arne Traulsen; Tom Lenaerts; Jorge M Pacheco
Journal:  Genes Cancer       Date:  2010-04

8.  Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions.

Authors:  Athar Aziz; E Joanna Baxter; Carol Edwards; Clara Yujing Cheong; Mitsuteru Ito; Anthony Bench; Rebecca Kelley; Yvonne Silber; Philip A Beer; Keefe Chng; Marilyn B Renfree; Kirsten McEwen; Dionne Gray; Jyoti Nangalia; Ghulam J Mufti; Eva Hellstrom-Lindberg; Jean-Jacques Kiladjian; Mary Frances McMullin; Peter J Campbell; Anne C Ferguson-Smith; Anthony R Green
Journal:  J Clin Invest       Date:  2013-04-01       Impact factor: 14.808

9.  Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.

Authors:  Kelly J Norsworthy; Eunpi Cho; Jyoti Arora; Jeanne Kowalski; Hua-Ling Tsai; Erica Warlick; Margaret Showel; Keith W Pratz; Lesley A Sutherland; Steven D Gore; Anna Ferguson; Sarah Sakoian; Jackie Greer; Igor Espinoza-Delgado; Richard J Jones; William H Matsui; B Douglas Smith
Journal:  Leuk Res       Date:  2016-09-03       Impact factor: 3.156

10.  Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion.

Authors:  David G Kent; Juan Li; Hinal Tanna; Juergen Fink; Kristina Kirschner; Dean C Pask; Yvonne Silber; Tina L Hamilton; Rachel Sneade; Benjamin D Simons; Anthony R Green
Journal:  PLoS Biol       Date:  2013-06-04       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.